Hepatocellular Carcinoma, Triple Negative Breast Cancer
Conditions
Brief summary
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy regimen for metastatic disease, and in male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed systemic therapy.
Interventions
DRUGeFT508
200 mg eFT508 dosed BID for 3 week cycles
Sponsors
Effector Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(TNBC Cohort Only): * Women ≥18 years of age * Pathologically documented diagnosis of TNBC that is metastatic or locally advanced and unresectable * Adequate hepatic function and coagulation profile * Negative HIV, HBV and HCV Inclusion Criteria (HCC Cohort Only): * Men or Women ≥18 years of age * Histological or cytological confirmed diagnosis of HCC with Barcelona Clinic Liver Cancer Stage B or C who cannot benefit from resection, local ablation, or chemoembolization * ECOG performance status of 0 or 1 * Has at least 1 measurable lesion based on irRECIST 1.1. * Negative HIV tests Inclusion Criteria (Either Cohort): * subject agrees to undergo a pre-treatment and an on-treatment biopsy of the tumor * Completion of all previous therapy for the treatment of cancer ≥3 weeks before the start of study drug * All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 before the start of study drug * Adequate bone marrow and renal function * Life expectancy of ≥3 months
Exclusion criteria
(Either Cohort): * Pregnant or breastfeeding * History of another malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin; in situ cervical carcinoma; adequately treated, papillary, noninvasive bladder cancer; other adequately treated Stage 1 or 2 cancers currently in complete remission; or any other cancer that has been in complete remission for ≥2 years. * Gastrointestinal disease that may interfere with drug absorption or with interpretation of GI AEs. * Known symptomatic brain metastases requiring ≥10 mg/day of prednisolone (or its equivalent). * Significant cardiovascular disease within 6 months prior to start of study drug * Ongoing risk for bleeding due to active peptic ulcer disease or bleeding diathesis or requirement for systemic anticoagulation with unfractionated heparin, low-molecular-weight heparin or heparin fractions, or oral anticoagulants. * Evidence of an ongoing systemic bacterial, fungal, or viral infection * Has received a live vaccine within 30 days of planned start of study drug * Major surgery within 4 weeks before the start of study drug * Prior solid organ or bone marrow progenitor cell transplantation * Prior therapy with any known inhibitor of MNK1 or MNK2 * Prior high dose chemotherapy requiring stem cell rescue * History of or active autoimmune disorders or other conditions that might impair or compromise the immune system * Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids * Use of a strong inhibitor or inducer of cytochrome P450 (CYP)3A4 within 7 days prior to the start of study drug or expected requirement for use of a strong CYP3A4 inhibitor or inducer during study participation * Need for proton pump inhibitors and histamine H2 blockers * Previously received investigational product in a clinical trial within 30 days or within 5 elimination half lives (whichever is longer) prior to the start of study drug, or is planning to take part in another clinical trial while participating in this study * HCC Cohort Only: Portal vein invasion at the main portal (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of biomarkers of antitumor activation | 28 days | Biomarkers of antitumor immune activation in pre- and on treatment tumor biopsies and peripheral blood cells |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Levels of eIF4E and phospho-eIF4E | up to 3 years | Assessment of eIF4E and phospho-eIF4E in tumor biopsies by immunohistochemistry, and in circulating peripheral blood cells by phospho-flow cytometry |
| Number of mutations | up to 3 years | Assessment of mutations will be determined for a subset of known cancer driver genes by sequencing tumor DNA |
| Objective tumor response | up to 3 years | determined by irRECIST 1.1, defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) |
| Molecular profiling of circulating lymphocytes and tumor-infiltrating lymphocytes (TILs) | up to 3 years | Includes determination of T cell clonality via T cell receptor sequencing |
| Proportion of subjects with TEAEs and SAEs | up to 3 years | — |
| PK plasma concentrations | up to 21 weeks | taken at the anticipated maximum and minimum plasma concentrations for eFT508 |
| Progression Free Survival | up to 3 years | as determined by irRECIST 1.1, defined as the interval from the start of study drug to the earlier of the first documentation of disease progression or death from any cause |
Countries
United States
Outcome results
None listed